||| Menü 
Firmenveranstaltungen, Neuemissionen

Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

Fusionen, Übernahmen

Personal, Belegschaft, Meldungen zu Produkten


Bankleitzahlen - online.de

Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment

F. Hoffmann-La Roche Ltd /
Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin
in people with HER2-positive early breast cancer with residual disease after
neoadjuvant treatment
. Processed and transmitted by West Corporation.
The issuer is solely responsible for the content of this announcement.

* At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-
positive early breast cancer setting did not have their breast cancer return
compared to 77.0% treated with Herceptin, an 11.3% improvement
* People who have residual disease after neoadjuvant treatment have a worse
prognosis than those with no detectable disease
* Data from the phase III KATHERINE study will be submitted to health
authorities globally, including the US Food and Drug Administration and
European Medicines Agency
* Results are being presented at the 2018 San Antonio Breast Cancer Symposium,
featured in the press programme and simultaneously published in the New
England Journal of Medicine on Wednesday, 5 December 2018
Basel, 5 December 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that
the phase III KATHERINE study met its primary endpoint, showing Kadcyla®
(trastuzumab emtansine) as a single agent significantly reduced the risk of
disease recurrence or death (invasive disease-free survival; iDFS) by 50%
(HR=0.50, 95% CI 0.39-0.64, p<0.0001) compared to Herceptin® (trastuzumab) as an
adjuvant (after surgery) treatment in people with HER2-positive early breast
cancer (eBC) who have residual disease (pathological invasive residual disease
in the breast and/or axillary nodes) present following neoadjuvant (before
surgery) treatment.[1] At three years, 88.3% of people treated with Kadcyla did
not have their breast cancer return compared to 77.0% treated with Herceptin, an
11.3% improvement.[1] Kadcyla improved iDFS irrespective of hormone receptor
status, lymph node status and prior HER2-targeted treatment regimen received in
the neoadjuvant setting.1 The safety profile of Kadcyla was consistent with that
seen in previous studies, and no unexpected or new safety signals were

"The KATHERINE results demonstrate a significant reduction in the risk of
recurrence of HER2-positive early breast cancer in people with residual disease
after neoadjuvant therapy, and we look forward to submitting these data to
health authorities as soon as possible," said Sandra Horning, MD, Roche's Chief
Medical Officer and Head of Global Product Development. "We come closer to the
goal of helping each person with early breast cancer have the greatest
opportunity for cure with every advance in reducing disease recurrence."

The goal in treating eBC is to provide people with the best chance for a cure,
which may involve treatment before and after surgery as part of a comprehensive
treatment approach. [4;5] While we come closer to this goal with each advance,
many people still have a disease recurrence in the long-term. [6] Neoadjuvant
treatment is given before surgery with the goal of shrinking tumours and helping
to improve surgical outcomes. [5;7;8] Adjuvant treatment is given after surgery
and is aimed at eliminating any remaining cancer cells in the body to help
reduce the risk of the cancer returning. [5]
These results are being presented in an oral session today at the 2018 San
Antonio Breast Cancer Symposium (SABCS) at 11.00 am CST (abstract GS1-10) and
featured in the official SABCS press programme at 07.15 am CST. These results
will simultaneously be published in the New England Journal of Medicine.

About the KATHERINE study [9]
KATHERINE is an international, multi-centre, two-arm, randomised, open-label,
phase III study evaluating the efficacy and safety of Kadcyla versus Herceptin
as an adjuvant therapy in people with HER2-positive eBC who have pathological
invasive residual disease in the breast and/or axillary lymph nodes following
neoadjuvant therapy that included Herceptin and taxane-based chemotherapy. The
primary endpoint of the study is iDFS, which, in this study is defined as the
time from randomisation free from invasive breast cancer recurrence or death
from any cause. Secondary endpoints include disease-free survival and overall

| KATHERINE Study Results([1]) |
|  |Kadcyla| Herceptin |
| | n=743 | n=743 |
|Median follow-up | 41 months |
| Invasive disease-free survival (iDFS) |
|Risk reduction |HR=0.50, 95% CI 0.39-0.64, p<0.0001 |
| | 88.3% | 77.0% |
|3-year iDFS +-------+----------------------------+
| | 11.3% improvement |
| Overall survival (OS) |
| |HR=0.70, 95% CI 0.47-1.05, p=0.0848 |
|Risk reduction | Data immature at this interim |
| | analysis |
| Adverse events (AEs) |
|Grade >=3 AE | 25.7% | 15.4% |
|Serious AE | 12.7% | 8.1% |
| Most common Grade >=3 AEs |
|Thrombocytopenia (decreased platelet | 5.7% | 0.3% |
|count) | | |
|Hypertension (high blood pressure) | 2.0% | 1.2% |
|Radiation-induced skin injury | 1.4% | 1.0% |
|Peripheral neuropathy (numbness, tingling| 1.4% | 0.0% |
|or pain in the hands or feet) | | |
|Neutropenia (decreased neutrophil count) | 1.2% | 0.7% |
|Hypokalaemia (low blood potassium level) | 1.2% | 0.1% |
|Fatigue | 1.1% | 0.1% |
|Anaemia (decrease in red blood cells) | 1.1% | 0.1% |

About Kadcyla
Kadcyla is an antibody-drug conjugate (ADC) engineered to deliver potent
chemotherapy directly to HER2-positive cancer cells, potentially limiting damage
to healthy tissues. [2;3] It combines two anti-cancer properties joined together
by a stable linker: the HER2-targeting properties of trastuzumab (the active
ingredient in Herceptin) and the chemotherapy agent DM1. [10] Kadcyla is the
only ADC approved as a single agent in 104 countries including the US and EU for
the treatment of people with HER2-positive metastatic breast cancer who have
previously received Herceptin and taxane chemotherapy, separately or in
combination. Roche licenses technology for Kadcyla under an agreement with
ImmunoGen, Inc.

About Roche's medicines for HER2-positive breast cancer
Roche has been leading research into the HER2 pathway for over 30 years and is
committed to improving the health, quality of life and survival of people with
both early and advanced HER2-positive disease. HER2-positive breast cancer is a
particularly aggressive form of the disease that affects approximately 15-20% of
patients. [11] Roche has developed three innovative medicines that have helped
transform the treatment of HER2-positive breast cancer: Herceptin (trastuzumab),
Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine). Eligibility for
treatment with Roche's HER2-targeted medicines is determined via a diagnostic
test, which identifies people who will likely benefit from these medicines at
the onset of their disease.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on
advancing science to improve people's lives. The combined strengths of
pharmaceuticals and diagnostics under one roof have made Roche the leader in
personalised healthcare - a strategy that aims to fit the right treatment to
each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated
medicines in oncology, immunology, infectious diseases, ophthalmology and
diseases of the central nervous system. Roche is also the world leader in in
vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in
diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose
and treat diseases and make a sustainable contribution to society. The company
also aims to improve patient access to medical innovations by working with all
relevant stakeholders. Thirty medicines developed by Roche are included in the
World Health Organization Model Lists of Essential Medicines, among them life-
saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth
consecutive year, Roche has been recognised as the most sustainable company in
the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100
countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche
invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more
information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

[1] Geyer, et al. KATHERINE trial. Presented at SABCS; 2018 Dec 4-8; San
Antonio, TX, USA. Abstract #GS1-10.
[2] Hurvitz SA, et al. J Clin Oncol. 2013;31(9):1157-63.
[3] Verma S, et al. N Engl J Med. 2012;367(19):1783-91.
[4] Scharl A, et al. Geburtshilfe Frauenheilkd. 2015;75(7):683-91.
[5] Johns Hopkins. Neoadjuvant and Adjuvant Chemotherapy. [Internet; cited 2018
November 29]. Available from: http://www.hopkinsmedicine.org/breast_center/
[6] Slamon D, et al. BCIRG 006 trial. Presented at: SABCS; 2015 Dec 6-10; San
Antonio, TX, USA. Abstract #S5-04.
[7] Abt NB, et al. JAMA Surg. 2014;149(10):1068-76.
[8] Kaufmann M, et al. Ann Surg Oncol. 2012;19(5):1508-16.
[9] ClinicalTrials.gov. A Study of Trastuzumab Emtansine Versus Trastuzumab as
Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual
Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
(KATHERINE). [Internet; cited 2018 November 29]. Available from:
[10] Junttila TT, et al. Breast Cancer Res Treat. 2011;128:347-56.
[11] Wolff AC, et al. J Clin Oncol. 2013;31(31):3997-4013.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow


This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: F. Hoffmann-La Roche Ltd via GlobeNewswire

 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Sehr gut

Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.094 Sekunden